Study to evaluate the efficacy of varying doses of study drug; CHF 718 beclomethasone dipropionate pressurized metered dose inhaler (pMDI), compared to QVAR & placebo; in the management of uncontrolled or poorly controlled, moderate asthma patients.
The study will last approximately 12 weeks for each subject and a total of 5 clinic visits will be performed during the study.
After a 2-week run-in period, subjects will enter the 8-week treatment period. Subjects will be randomized to 1 of 5 treatments, in a double-blind fashion (study subject & study doctor are blinded to the treatment assigned). Treatments assigned are 3 varying doses of the study drug, beclomethaone dipropionate
pMDI, compared to QVAR and placebo.